ARCT Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -17.78% compared to Arcturus Therapeutics Holdings's net margin of --. Arcturus Therapeutics Holdings's return on equity of -23.32% beat Armata Pharmaceuticals's return on equity of --.

Arcturus Therapeutics Holdings has a consensus price target of $79.47, signalling upside risk potential of 316.72%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 235.11%. Given that Arcturus Therapeutics Holdings has higher upside potential than Armata Pharmaceuticals, analysts believe Arcturus Therapeutics Holdings is more attractive than Armata Pharmaceuticals.

Arcturus Therapeutics Holdings has a beta of 2.635, which suggesting that the stock is 163.508% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.895%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $38.8M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Arcturus Therapeutics Holdings's net income of -$6.9M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 3.61x versus 756.79x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -17.78% compared to Arcturus Therapeutics Holdings's net margin of --. Arcturus Therapeutics Holdings's return on equity of -23.32% beat Perspective Therapeutics's return on equity of --.

Arcturus Therapeutics Holdings has a consensus price target of $79.47, signalling upside risk potential of 316.72%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Perspective Therapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.635, which suggesting that the stock is 163.508% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $38.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Arcturus Therapeutics Holdings's net income of -$6.9M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 3.61x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -17.78% compared to Arcturus Therapeutics Holdings's net margin of 10.05%. Arcturus Therapeutics Holdings's return on equity of -23.32% beat Electromed's return on equity of 15.62%.

Arcturus Therapeutics Holdings has a consensus price target of $79.47, signalling upside risk potential of 316.72%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 5.67%. Given that Arcturus Therapeutics Holdings has higher upside potential than Electromed, analysts believe Arcturus Therapeutics Holdings is more attractive than Electromed.

Arcturus Therapeutics Holdings has a beta of 2.635, which suggesting that the stock is 163.508% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $38.8M, which are larger than Electromed quarterly revenues of $14.7M. Arcturus Therapeutics Holdings's net income of -$6.9M is lower than Electromed's net income of $1.5M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Electromed's PE ratio is 43.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 3.61x versus 4.88x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -17.78% compared to Arcturus Therapeutics Holdings's net margin of 18.02%. Arcturus Therapeutics Holdings's return on equity of -23.32% beat Protalix BioTherapeutics's return on equity of -29.54%.

Arcturus Therapeutics Holdings has a consensus price target of $79.47, signalling upside risk potential of 316.72%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 527.8%. Given that Protalix BioTherapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Protalix BioTherapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.635, which suggesting that the stock is 163.508% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $38.8M, which are larger than Protalix BioTherapeutics quarterly revenues of $18M. Arcturus Therapeutics Holdings's net income of -$6.9M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 3.61x versus 3.84x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.